Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Chain Pharmacies’ Drug Price Settlement Rate in June Triples from 2 Years Ago
July 23, 2014
- MHLW FY2015 Budget Request to Center on PM Abe’s Growth Strategy
July 22, 2014
- ICH M7 Guideline Reaches Step 4; MHLW to Issue Notification
July 22, 2014
- Ministry Panel Agrees to Add Kitasato Daiichi Sankyo Vaccine’s Squarekids to Routine Vaccine Program
July 18, 2014
- Post-Shipment Quality Control Testing of Radiopharmaceuticals Would Not Violate GMP: MHLW
July 18, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 2: Prof. Kageyama of Jikei Univ.
July 18, 2014
- MOF Official in Charge of Health Spending to “Carefully” Discuss Budgets
July 17, 2014
- Council OKs Public-Knowledge Based Application for Oxaliplatin at Doses Approved Overseas
July 16, 2014
- 50% Price Rule, Unifying Price Brackets Starters of Next Generic Price Revision Discussions: Ministry Official
July 15, 2014
- MHLW Panel to Elaborate Proposed Scheme to Broaden Drug Development Requests
July 15, 2014
- Editor’s Pick: Five Healthcare News Headlines for June 30 - July 11
July 14, 2014
- Revised PAL to Go Live on November 25: Ministry Exec
July 14, 2014
- Science Ministry’s Updated Guidelines to Require Research Data Preservation
July 14, 2014
- Draft Policy on Resource Allocation Focuses Funding on 9 Fields of Healthcare R&D
July 14, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima
July 14, 2014
- Unami Tapped as New Budget Examiner for Health Finances
July 11, 2014
- PFSB Announces Final Draft of Drug Interaction Guidelines
July 11, 2014
- Utsunomiya to Move to National Center for Global Health and Medicine
July 10, 2014
- MHLW Orders Revisions of Precaution Statements for a Number of Drugs Including Forteo and Paxil
July 10, 2014
- MHLW Releases Report on Medical Database Project
July 9, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…